ISPOR - Session

Treatment-Related Costs of Ponatinib and Asciminib in Adults Patients with T315I-Positive Chronic Phase Chronic Myeloid Leukemia with Resistance or Intolerance to at Least Two Prior Kinase Inhibitors in the United States

May 6, 2024, 11:30 AM